Ornithine decarboxylase activity in tumor cell lines correlates with sensitivity to cell death induced by histone deacetylase inhibitors

被引:17
|
作者
Saunders, Laura R. [1 ]
Verdin, Eric [1 ]
机构
[1] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA
关键词
INTESTINAL EPITHELIAL-CELLS; POLYAMINE DEPLETION; CHROMATIN STRUCTURE; TOPOISOMERASE-II; GENE-EXPRESSION; CANCER-CELLS; C-MYC; APOPTOSIS; CYCLE; ACTIVATION;
D O I
10.1158/1535-7163.MCT-06-0298
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inhibitors of histone deacetylases (HDAC) show significant promise as targeted anticancer agents against a variety of hematologic and solid tumors. HDAC inhibitors arrest the growth of primary cells, but they induce apoptosis or differentiation of tumor cells. Although the precise mechanism is unknown, differences in cell cycle checkpoints and chromatin structure may be responsible. Cellular polyamines regulate both cell cycle progression and chromatin structure. In tumors, polyamines are abundantly produced because of increased activity of the rate-limiting enzyme in polyamine synthesis, ornithine decarboxylase (ODC). To determine if polyamines contribute to the cellular response to HDAC inhibitors, we inhibited ODC activity with alpha-difluoromethylornithine. Polyamine depletion increased resistance to apoptosis induced by HDAC inhibitors. In addition, we found that ODC activity levels correlated with sensitivity to HDAC inhibitors in a panel of tumor cell lines. We conclude that polyamines participate in the cellular response to HDAC inhibitors and that ODC activity correlates with sensitivity to HDAC inhibitor-induced apoptosis. Thus, elevated polyamine levels might be a biomarker for tumor sensitivity to HDAC inhibitor-induced apoptosis. These findings warrant clinical evaluation of tumor samples to determine if high ODC activity levels predict sensitivity to HDAC inhibitors.
引用
收藏
页码:2777 / 2785
页数:9
相关论文
共 50 条
  • [31] Histone deacetylase inhibitors for stem cell boost
    Darren J. Burgess
    Nature Reviews Genetics, 2014, 15 (6) : 364 - 364
  • [32] Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors
    Song, Hui
    Li, Chia-Wei
    Labaff, Adam M.
    Lim, Seung-Oe
    Li, Long-Yuan
    Kan, Shu-Fen
    Chen, Yue
    Zhang, Kai
    Lang, Jingyu
    Xie, Xiaoming
    Wang, Yan
    Huo, Long-Fei
    Hsu, Sheng-Chieh
    Chen, Xiaomin
    Zhao, Yingming
    Hung, Mien-Chie
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 404 (01) : 68 - 73
  • [33] Histone deacetylase inhibitors enhance retinoid response in human breast cancer cell lines
    Emionite, L
    Galmozzi, F
    Grattarola, M
    Boccardo, F
    Vergani, L
    Toma, S
    ANTICANCER RESEARCH, 2004, 24 (06) : 4019 - 4024
  • [34] Radiosensitization by histone deacetylase inhibitors +/- demethylating agents in head and neck cancer cell lines
    De Schuller, H.
    Van Criekinge, W.
    Nuyts, S.
    EJC SUPPLEMENTS, 2007, 5 (08): : 23 - 23
  • [35] Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines
    Gray, SG
    Qian, CN
    Furge, K
    Guo, X
    Teh, BT
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2004, 24 (04) : 773 - 795
  • [36] Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines
    Kisseberth, William C.
    Murahari, Sridhar
    London, Cheryl A.
    Kulp, Samuel K.
    Chen, Ching-Shih
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2008, 69 (07) : 938 - 945
  • [37] Differential expression of ornithine decarboxylase antizyme inhibitors and antizymes in rodent tissues and human cell lines
    Bruno Ramos-Molina
    Andrés J. López-Contreras
    Asunción Cremades
    Rafael Peñafiel
    Amino Acids, 2012, 42 : 539 - 547
  • [38] Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines
    Sakajiri, S
    Kumagai, T
    Kawamata, N
    Saitoh, T
    Said, JW
    Koeffler, HP
    EXPERIMENTAL HEMATOLOGY, 2005, 33 (01) : 53 - 61
  • [39] Histone deacetylase inhibitors reverse EMI phenotype and chemoresistance in pancreatic cancer cell lines
    Fournier, Keith
    Choi, Woonyoung
    Maarquis, Lauren
    McConkey, David J.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [40] Differential expression of ornithine decarboxylase antizyme inhibitors and antizymes in rodent tissues and human cell lines
    Ramos-Molina, Bruno
    Lopez-Contreras, Andres
    Cremades, Asuncion
    Penafiel, Rafael
    AMINO ACIDS, 2012, 42 (2-3) : 539 - 547